Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for...

Area of Science:

• Cardiology
• Hematology
• Biochemistry

Background:

• Iron overload cardiomyopathy is a primary cause of mortality in thalassemia patients.
• Despite advancements in iron chelation therapy, heart failure mortality remains high.
• Limited understanding of cardiomyocyte iron uptake mechanisms hinders effective treatment.

Purpose of the Study:

• To review and summarize the known routes of iron entry into cardiomyocytes.
• To discuss the evidence supporting or refuting each identified iron uptake pathway.
• To inform the development of improved therapeutic strategies for thalassemic iron overload cardiomyopathy.

Main Methods:

• Comprehensive literature review of studies on iron uptake in cardiomyocytes.
• Analysis of evidence from pharmacological interventions targeting iron transport.
• Synthesis of data on L-type calcium channels (LTCC), T-type calcium channels (TTCC), divalent metal transporter 1 (DMT1), and transferrin receptors (TfRs).

Main Results:

• Multiple pathways facilitate iron entry into cardiomyocytes during iron overload.
• L-type and T-type calcium channels, DMT1, and TfRs are implicated in cardiomyocyte iron uptake.
• Pharmacological evidence provides support and challenges for the role of each pathway.

Conclusions:

• Clarifying iron entry routes is essential for advancing thalassemia treatment.
• Targeting specific iron transport mechanisms may offer novel therapeutic avenues.
• Further research is needed to fully elucidate and exploit these pathways for clinical benefit.